AU2003303231A1 - Benzoxazines and derivatives thereof as inhibitors of pi3ks - Google Patents

Benzoxazines and derivatives thereof as inhibitors of pi3ks

Info

Publication number
AU2003303231A1
AU2003303231A1 AU2003303231A AU2003303231A AU2003303231A1 AU 2003303231 A1 AU2003303231 A1 AU 2003303231A1 AU 2003303231 A AU2003303231 A AU 2003303231A AU 2003303231 A AU2003303231 A AU 2003303231A AU 2003303231 A1 AU2003303231 A1 AU 2003303231A1
Authority
AU
Australia
Prior art keywords
pi3ks
benzoxazines
inhibitors
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003303231A
Other languages
English (en)
Inventor
Rocco Dean Gogliotti
Keri Lynn Muccioli
Kimberly Suzanne Para
Melean Visnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU2003303231A1 publication Critical patent/AU2003303231A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003303231A 2002-12-20 2003-12-10 Benzoxazines and derivatives thereof as inhibitors of pi3ks Abandoned AU2003303231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43522702P 2002-12-20 2002-12-20
US60/435,227 2002-12-20
PCT/IB2003/005887 WO2004056820A1 (en) 2002-12-20 2003-12-10 Benzoxazines and derivatives thereof as inhibitors of pi3ks

Publications (1)

Publication Number Publication Date
AU2003303231A1 true AU2003303231A1 (en) 2004-07-14

Family

ID=32682185

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003303231A Abandoned AU2003303231A1 (en) 2002-12-20 2003-12-10 Benzoxazines and derivatives thereof as inhibitors of pi3ks

Country Status (8)

Country Link
US (1) US20040138199A1 (enExample)
EP (1) EP1581529A1 (enExample)
JP (1) JP2006512357A (enExample)
AU (1) AU2003303231A1 (enExample)
BR (1) BR0317572A (enExample)
CA (1) CA2510851A1 (enExample)
MX (1) MXPA05006742A (enExample)
WO (1) WO2004056820A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1648422A4 (en) * 2003-07-28 2007-09-19 Reddys Lab Inc Dr TREATMENT AND PREVENTION OF CARDIOVASCULAR ACCIDENTS
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US7914831B2 (en) 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
EP1750714A1 (en) * 2004-05-13 2007-02-14 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
KR101229647B1 (ko) 2004-09-03 2013-02-05 메르크 세로노 에스.에이. 피리딘 메틸렌 아조리디논 및 포스포이노시타이드 저해제의용도
US7691888B2 (en) 2004-10-07 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-indazole
US20080287469A1 (en) * 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
EP2248532A1 (en) * 2005-08-09 2010-11-10 Metaproteomics, LLP Protein kinase modulation by hops and acacia products cross-reference to related applications
ZA200801822B (en) 2005-08-26 2009-09-30 Serono Lab Pyrazine derivatives and use as p13k inhibitors
CA2618489A1 (en) * 2005-09-07 2007-03-15 Laboratoires Serono S.A. Pi3k inhibitors for the treatment of endometriosis
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
NZ568860A (en) * 2005-12-09 2012-09-28 Metaproteomics Llc Protein kinase modulation by hops and acacia products
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
ZA200904857B (en) 2007-02-22 2010-09-29 Merck Serono Sa Quinoxaline compounds and use thereof
WO2009026345A1 (en) * 2007-08-20 2009-02-26 Targegen Inc. Thiazolidinone compounds, and methods of making and using same
EP2341052A4 (en) * 2008-09-05 2011-10-12 Shionogi & Co RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
WO2010091996A1 (en) 2009-02-12 2010-08-19 Merck Serono S.A. 2-morpholino-pyrido[3,2-d]pyrimidines
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
JP2012524126A (ja) 2009-04-20 2012-10-11 ギリアド カリストガ リミテッド ライアビリティ カンパニー 固形腫瘍の治療方法
MX2011012584A (es) * 2009-05-26 2012-02-21 Exelixis Inc Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación.
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
AR078770A1 (es) 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
MX2012005518A (es) * 2009-11-13 2012-06-19 Merck Serono Sa Derivados de pirazol amina triciclica.
WO2012130306A1 (en) 2011-03-30 2012-10-04 Elara Pharmaceuticals Gmbh Bicyclic 2,3-dihyrdobenzazine compounds for use in therapy
CN102731525A (zh) * 2011-04-08 2012-10-17 上海艾力斯医药科技有限公司 苯并吗啉衍生物
IN2014CN04174A (enExample) 2011-12-22 2015-09-04 Novartis Ag
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
EP3083630B1 (en) 2013-12-20 2019-08-21 Gilead Calistoga LLC Process methods for phosphatidylinositol 3-kinase inhibitors
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
ME03316B (me) * 2014-06-30 2019-10-20 Astrazeneca Ab Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
WO2016179343A1 (en) 2015-05-05 2016-11-10 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
US11351156B2 (en) 2017-10-13 2022-06-07 Inserm Combination treatment of pancreatic cancer
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
CN120398870A (zh) * 2024-01-31 2025-08-01 深圳晶蛋生物医药科技有限公司 一种苯并吗啉类化合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355664B1 (en) * 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
DE60144277D1 (de) * 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
MXPA05000453A (es) * 2002-07-10 2005-03-23 Applied Research Systems Derivados de benceno fusionados a azolidinona-vinilo.
US20040092561A1 (en) * 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
US20040214872A1 (en) * 2002-09-26 2004-10-28 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof

Also Published As

Publication number Publication date
JP2006512357A (ja) 2006-04-13
CA2510851A1 (en) 2004-07-08
US20040138199A1 (en) 2004-07-15
MXPA05006742A (es) 2005-09-08
EP1581529A1 (en) 2005-10-05
WO2004056820A1 (en) 2004-07-08
BR0317572A (pt) 2005-11-22

Similar Documents

Publication Publication Date Title
AU2003280188A1 (en) Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
AU2003251559A1 (en) Heterocyclic inhibitors of kinases
AU2003237121A1 (en) Pyrrole derivatives as inhibitors of erk2 and uses thereof
AU2003235676A1 (en) Tricyclic-bis-enone derivatives and methods of use thereof
AU2003261434A1 (en) Iminothiazolidinones as inhibitors of hcv replication
AU2003256297A1 (en) Benzimidazoles and benzothiazoles as inhibitors of map kinase
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
AU2003261449A1 (en) Compositions for rna interference and methods of use thereof
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
AU2002228316A1 (en) Carbazole derivatives and their uses as heparanase inhibitors
AU2002305205A1 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
AU2003259735A1 (en) Small-mer compositions and methods of use
AU2003218758A1 (en) Derivatives of 1-phenyl-3-phenylpyrazole as herbicides
AU2003293356A1 (en) Dihydropyridinone derivatives as hne inhibitors
AU2003243318A1 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
AU2003217105A1 (en) Novel of cytokine inhibitors
AU2003202116A1 (en) Nicotinamide derivatives useful as pde4 inhibitors
AU2003299441A1 (en) Nf-hev compositions and methods of use
AU2003292696A1 (en) Metastin derivative and use thereof
AU2003300692A1 (en) Stable formulations of ace inhibitors and methods for preparation thereof
AU2003210983A1 (en) Kinase inhibitors and methods of use thereof
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
AU2003268464A1 (en) INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
AU2002230056A1 (en) Indole derivatives and their uses as heparanase inhibitors
AU2003218715A1 (en) Azepane derivatives and their use as atk1 inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase